No Data
Suzhou Highfine Biotech Co., Ltd.'s (SZSE:301393) Largest Shareholder, CEO Yong Zhu Sees Holdings Value Fall by 7.4% Following Recent Drop
Additional Considerations Required While Assessing Suzhou Highfine Biotech's (SZSE:301393) Strong Earnings
Haofan Biology (301393.SZ): has cumulatively repurchased 0.95% of the shares.
GeLongHui November 1st | HaoFan Bio (301393.SZ) announced that as of October 31, 2024, the company has repurchased a total of 1,028,148 shares of the company through a designated securities account in a centralized auction trading method, accounting for 0.95% of the company's current total share capital. The highest fill price was 51.50 yuan/share, the lowest fill price was 33.46 yuan/share, and the total fill price amount was 41.9958 million yuan (excluding trading expenses).
Haofan Biology (301393.SZ): In 2024, the mid-year options distribution is 1.25 yuan per share, with a record date of November 8.
Gelonghui, November 1st | Haofan Biology (301393.SZ) announced that the company's 2024 mid-term equity distribution plan is: based on a total share capital of 106,971,852.00 shares excluding repurchased shares of 1,028,148.00 shares, each shareholder will receive RMB 1.250000 in cash (tax included) for every 10 shares held. The registration date for this equity distribution is November 8, 2024, and the ex-dividend date is November 11, 2024.
Haofan Biotech: Report for the third quarter of 2024
Has Suzhou Highfine Biotech Co., Ltd.'s (SZSE:301393) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
Should Weakness in Suzhou Highfine Biotech Co., Ltd.'s (SZSE:301393) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?
No Data
